v3.26.1
Segment Information - Summarizes of Significant Expenses (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Segment Reporting Information [Line Items]      
Cost of sales $ 124,032 $ 140,688 $ 146,853
Research and development expenses 216,180 270,661 350,187
Selling, general and administrative expenses 332,979 420,922 598,250
Operating Segments      
Segment Reporting Information [Line Items]      
Revenues 386,013 361,374 470,170
Cost of sales 124,032 140,688 146,853
Selling, general and administrative expenses 332,979 420,922 598,250
Other segment income (expense) [1] 88,342 511,553 504,262
Net income (loss) attributable to shareholders of Sinovac (198,836) 40,656 (120,858)
Operating Segments | Pneumococcal Conjugate Vaccine      
Segment Reporting Information [Line Items]      
Research and development expenses 38,859 43,228 44,121
Operating Segments | Bivalent Enterovirus Vaccine      
Segment Reporting Information [Line Items]      
Research and development expenses 19,995 13,722 6,659
Operating Segments | Pentavalent DTaP-IPV/Hib Combination Vaccine      
Segment Reporting Information [Line Items]      
Research and development expenses 17,325 33,767 93,211
Operating Segments | Rabies Vaccine for Human Use      
Segment Reporting Information [Line Items]      
Research and development expenses 15,507 45,641 28,365
Operating Segments | Group ACYW135 Meningococcal Conjugate Vaccine      
Segment Reporting Information [Line Items]      
Research and development expenses 13,522 21,647 29,174
Operating Segments | Adsorbed Tetanus Vaccine      
Segment Reporting Information [Line Items]      
Research and development expenses 11,772 7,725 1,365
Operating Segments | Others      
Segment Reporting Information [Line Items]      
Research and development expenses [2] $ 99,200 $ 104,931 $ 147,292
[1] Other segment income (expense) includes provision for credit losses, loss on disposal and impairment of property, plant and equipment, loss on impairment of intangible assets, loss on impairment of goodwill, government grants recognized in income, interest and financing expenses, interest income, share of losses from equity method investments, income tax benefit (expense), and other income, net.
[2] Includes research and development expenses on other product candidates at preliminary stage.